Most significantly CDKN2A loss and RB1 loss are mutually exclusive in most cancers that lose these genes at a significant level (>5%), suggesting that the control of CDK4/6 activity and RB-status appear to define a single element of the pathway (Fig. 1e and Supplementary Figs. 2–4). This evidence concerns the gene CDKN2A and cancer.